Will Higher Keytruda Sales Drive Merck's Q1
25/4 03:51
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates. As usual, Keytruda will be the driving growth for Merck with quarterly sales est...